DSpace JSPUI

1. Elea
2. Dipartimenti e Centri di ricerca UniSA. Pubblicazioni scientifiche
3. Translational Medicine @ UniSa
4. Translational Medicine @ UniSa. Volume 15 (may. - aug. 2016)

Abstract:

T-large granular lymphocyte leukemia (T-LGLL) is a chronic clonal proliferation of effector memory cytotoxic CD3+CD57+CD56- T cells and the current guidelines suggest immunosuppressive therapy as first-line therapy, but the treatment of refractory/relapsed patients is still challenging due to the lack of prospective studies. We describe a series of two refractory/relapsed T-LGLL patients successfully treated with bendamustine, a chemotherapeutic agent largely used for B-cell neoplasms, but poorly investigated for the treatment of T-cell diseases. Complete remission (CR) was achieved in 3 and 6 months, respectively, and maintained for at least 20 months. One patient relapsed after a 20-month CR, but she was responsive to bendamustine therapy again, obtaining a further prolonged CR. Bendamustine as single agent or in combination could be a feasible therapeutic option in refractory/relapsed T-LGLL, especially for elderly patients because of its safety profile.

Appears in Collections:

Translational Medicine @ UniSa. Volume 15 (may. - aug. 2016)

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.